Fig. 7: Synthetic lethality as a therapeutic paradigm in NSCLC cancer.
From: miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

The simultaneous mutation of RAS and upregulation of CDK1 confer complete lethality, whereas any other combination of mutations is viable.